One Nucleus and Life Science Nation unite for the Genesis 2024 and Redefining Early Stage Investments (RESI) Conferences to Amplify Impact on Life Science Innovation. 

1 Aug

By Dennis Ford, Founder and CEO of Life Science Nation

Boston MA and London UK, 31 July 2024 - One Nucleus and Life Science Nation (LSN) are pleased to announce the co-location of their renowned Genesis 2024 and Redefining Early Stage Investments (RESI) conferences, scheduled to take place on 4 December 2024, in London. The Genesis Conference programme will be at 1 Wimpole Street, and RESI will be at 11 Cavendish Square, allowing attendees to participate in either or both events just a few steps away from each other. This unprecedented collaboration aims to connect early-stage life science companies to LSN’s global network of capital investors and licensing partners under the theme of “Maximising Returns from Life Science Innovation.”

For over two decades, the Genesis Conference has been a cornerstone event, bringing together top opinion leaders and stakeholders in life sciences to discuss critical trends, catalyse partnerships, and shape the industry’s future landscape. With its rich history of fostering innovation and facilitating meaningful connections, Genesis has consistently delivered high-value content through keynote presentations, panels, and networking opportunities.

LSN’s RESI conference series is known for being able to match up startup companies seeking seed funds up to 2 million, series A and series B, with global partners. RESI complements Genesis by focusing on early-stage companies and their interaction with investors and partners across the “4 Ds” of Drugs, Devices, Diagnostics, and Digital Health. Integrating RESI’s expertise in matchmaking and Genesis’s comprehensive content programme, the co-located events promise an unparalleled experience for UK delegates and RESI international investors interested in the early-stage assets coming out of locations including Cambridge, London and Oxford.

Key highlights of the co-located conferences include:

  • A diverse mix of high-content keynote presentations and expert panels addressing cutting-edge industry topics.
  • A dedicated RESI interactive partnering, offering both in-person and virtual days that match startups based on the stage of development and product with investors and licensing partners that are the right fit.
  • A dedicated Genesis 2024 Conference App where information is shared, connections are made and is the route to access 1-2-1 Genesis partnering, programme, sponsor, and exhibitor details.
  • Extensive networking opportunities with over 500 industry delegates expected to attend these events, making this one of Europe’s largest life science investor meetings in 2024.
  • Genesis Fringe events offer deeper technical and business insights and enhanced in-person networking.
  • An Exhibition providing a dynamic forum for dialogue and visibility among partners and customers.
  • 20 Innovator’s Pitch Challenge (IPC) slots available. The IPC allows early-stage life science and healthcare companies to engage more with conference attendees and pitch directly to a panel of active investors and industry experts. Applications to apply are open until Friday 25 October.

“We are thrilled to bring together the RESI global investor network with Genesis, a One Nucleus flagship UK event which will add some excitement and facilitate some foreign investment into the life science ecosystem,” said Dennis Ford, CEO of Life Science Nation. “The co-location of  the two conferences represents a significant milestone in fostering collaboration and innovation across the life sciences sector, enabling us to amplify our impact on early-stage companies and investors globally.”

Tony Jones, CEO of One Nucleus, added, “Genesis has always been about shaping the future of life sciences through meaningful dialogue and strategic partnerships. Teaming up with RESI allows us to expand these efforts, creating synergies that benefit our members and the broader life sciences community.”

For more information about the RESI and Genesis conferences, including sponsorship opportunities and registration details, please visit RESI and genesisconference.com.

About Life Science Nation (LSN): Life Science Nation (LSN) is a global partnering ecosystem connecting early-stage companies with investors and partners across Drugs, Devices, Diagnostics, and Digital Health. LSN curates databases of global investors and technology assets, providing sourcing, ranking, and accelerator services through initiatives like RESI and Focus on Cures Accelerator (FOC).

About One Nucleus: One Nucleus is an international membership organisation for life science and healthcare companies. Based in Cambridge, UK, One Nucleus supports its members through networking, knowledge-sharing, and advocacy initiatives, promoting growth and innovation within the life sciences community.

Media Contact Information: 

Media Contacts:
Caitlin Dolegowski, Marketing Manager
c.dolegowski@lifesciencenation.com

Tony Jones, CEO
tony@onenucleus.com

For Conference Inquiries:
Genesis: Claire Abrams - genesis@onenucleus.com
RESI: Claire Jeong - c.jeong@lifesciencenation.com

RESI-London-2024-1100px

Breaking Barriers in Science: The Journey of Meritxell Teixidó and Gate2Brain

31 Jul

Interview with Meritxell Teixidó, PhD, CEO & CSO, Gate2Brain By Caitlin Dolegowski, Marketing Manager, LSN

Meritxell-TeixidóMeritxell Teixidó CaitiCaitlin Dolegowski

Meritxell Teixidó holds a PhD in Organic Chemistry from the University of Barcelona (UB) and an eMBA in Entrepreneurship, Innovation and International Business from UOC. At a scientific level, her field is the synthesis of peptides and the discovery of peptides capable of crossing biological barriers and she was responsible for this research line at the IRB Barcelona during more than 15 years, where she co-directed 10 doctoral theses, published more than 50 articles and participated in 9 patents.

After dedicating more than 15 years to biomedical research at IRB Barcelona, trying to improve the arrival of drugs to the brain by crossing the blood-brain barrier that protects it. She decided to jump more barriers and be the CEO/CSO of Gate2Brain SL. in order to bring technology closer to patients, a challenge and an honor. Jumping barriers is perhaps the common thread that describes her, combining science and innovation with a new vision on leadership, for which she received the Spanish Woman Startup Award 2022 – Inspiration.

Caitlin Dolegowski (CD): Please introduce Gate2Brain and the company’s technology.

Meritxell Teixidó (MT): Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier using a radically innovative peptide-based patented technology platform.

G2B-002, the first therapeutic proof of concept of our technology platform, is aimed mainly at the treatment of rare pediatric solid tumors.

CD: Meritxell, you were joined by your colleague, Carles Taulé, Gate2Brain’s Business Development Manager, at RESI Europe and Gate2Brain boasts three women founders. Tell us more about your team.

MT: Gate2Brain has a multidisciplinary team that ranges from peptide scientists to oncologist, from business development to operations. A team that is based in Barcelona and Madrid in Spain but also has key members in Tel Aviv and Mumbai.

CD: What were your experiences at the conference? What worked well for both you and Carles at RESI Europe?

MT: The conference was a great opportunity to share the journey of Gate2Brain and interact with novel potential investors that could help us advance to the clinics.

CD: What stage of fundraising is Gate2Brain in and what are your goals for the rest of 2024 and looking into 2025?

MT: We are fundraising 5M€ to perform the preclinical regulatory studies of G2B-002 (IND enabling studies) and prepare the Clinical Batch of G2B-002.

CD: Congratulations on your first-place finish at RESI Europe’s Innovator’s Pitch Challenge (IPC)! There were over 40 companies in the IPC. What do you think was the key to your success and standing out at RESI Europe?

MT: On one hand, the impact that our technology could have on the first indication that will benefit from it, pediatric brain tumors that have no cure to date. On the other hand, the potential to use our delivery platform to improve the transport of many other drug candidates for brain diseases that are not able to cross the BBB unaided. Our Intelectual property portafolio and the team behind the scenes are to hallmarks that positionates Gate2Brain.

CD: What advice would you like to give to fellow entrepreneurs about RESI conferences?

MT: RESI is the perfect arena to establish connections and network with investors that are aligned with early drug development.

RESI-Boston-2024-September-1100pxw

RESI-London-2024-1100px

RESI-SF-2025-Banner-1100px

Hot Investor Profile: USA-Based Single Family Office Seeks to invest in Pre-Seed and Seed Stage Therapeutics Addressing CNS and Oncology Indications

25 Jul

A single family office based in the US actively invests in pre-seed and seed-stage companies, and occasionally invests in Series A rounds as well. The firm is open to global companies, including those in emerging countries. 
 
The firm is most interested in therapeutics opportunities and in terms of indication, the firm is most interested in oncology and CNS. The firm is open to various modalities but has mostly looked at small molecule and some peptide drugs. In addition, the firm is also interested in repurposed assets that have initially been shelved by big pharma. In terms of stage of development, the firm will look at pre-clinical and early clinical opportunities. The firm is also interested in diagnostics and some digital health. Their interests in healthtech include technologies that help health systems reduce costs, B2C products in mental health (especially pediatric) and chronic disease, and more. 
 
The firm does not have specific company or management team requirements. The firm prefers to co-invest alongside likeminded investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Europe-Based VC Seeks to Invest in Pre-Clinical Therapeutics Companies in Oncology, Immunology, Rare Diseases, and More 

25 Jul

A venture capital firm founded in 2021 and located in Europe is currently investing out of their first fund and looks to invest in early-stage life science companies in the therapeutics space. The firm focuses on Seed investments in the form of equity. Typical allocation is up to $5M for the first ticket. The firm invests in European companies. 
 
The firm is interested in therapeutics, with a focus on oncology, immunology, rare diseases, fibrotic diseases and CNS. The firm will invest in pre-clinical therapeutic companies. 
 
The firm has no specific company or management team requirements and is willing to work with all early-stage companies globally, with promising technologies. The firm prefers to lead investments and seeks board seat representation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: US-Based VC Invests in Pre-Seed and Seed Companies Across Medtech and Digital Health Sectors

25 Jul

A US-based venture fund invests only in seed and pre-seed rounds, and focuses solely on opportunities in healthcare IT, medtech and consumer health. The firm primarily invests in U.S. based companies but can invest in any geography. 
 
The firm invests in very early stage companies across the healthcare innovation ecosystem, including healthcare IT, medical devices, and consumer health. The firm is highly interested in preventative healthcare, future of work and healthcare IT applications. The firm is open to investing in any area of medicine, but has specific interest in opportunities in cardiology, pulmonary diseases, diabetes, and women’s health. 
 
The firm does not invest in companies that have already raised over $5 million in dilutive capital. The firm seeks to invest in high quality management teams, and prefers to work with experienced entrepreneurs that have a proven track record in their sector.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Global Pharmaceutical Looks For Early-Stage Strategic Partnerships With Therapeutic Programs in Dermatology

25 Jul

A global pharmaceutical firm specialized in the dermatology sector engages in partnerships with early stage companies; these relationships may take a variety of forms, but in most cases the firm forms a partnership around an asset and does not act as a minority equity investor. The firm partners with dermatology startups all around the globe. 
 
The firm is interested in therapeutic programs in the dermatology space, including in acne, dermatology-oncology, and rare diseases of the skin.  The firm will consider partnerships at any stage of development but will only make early stage partnerships if the asset’s risk profile is reasonable. 
 
There are no specific requirements for company and the management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

What would a Harris administration mean for biotech investment?

25 Jul

By Dennis Ford, Founder and CEO of Life Science Nation

With Vice President Kamala Harris in the spotlight for the presidency, what would her administration mean for biotech investment and partnerships? Here’s some commentary and a look at her past and potential future impact:

Science

Harris, the daughter of a breast cancer researcher, is strongly pro-science. She has advocated for COVID-19 vaccines, followed CDC guidance, and increased the NIH budget. During the 2020 VP debates, she criticized her opponent for not believing in science. Publications like Scientific American and Nature have praised her. She would likely leverage federal resources to advance science, particularly healthcare and climate.

Drug Pricing

Harris is known for her progressive stance on drug pricing. As California’s AG, she won lawsuits against big pharma for marketing and pricing issues and played a key role in lowering insulin prices. Her “Medicare for All” plan proposed allowing HHS to negotiate drug prices and supported “march-in rights” to control certain patents. She advocated for linking U.S. drug prices to those negotiated by other governments and proposed taxing profits from “abusive drug pricing” at 100%. However, many of these measures faced opposition and were not passed. Harris would likely continue pushing for drug price reductions and Medicare expansion.

Pharmacy Benefit Managers (PBMs)

Lawmakers are increasingly scrutinizing PBMs for their role in drug pricing. The FTC is suing several large PBMs, and the House Oversight and Accountability Committee is holding hearings on their practices. While Harris is not central to these actions, the evolving situation may influence her approach to drug pricing.

Payors

Harris has opposed the rising power of health insurers, notably suing to stop the Cigna-Anthem merger in 2015-2016. In 2021, she supported expanding Medicare and private insurance coverage, particularly in maternal care and disadvantaged communities. Harris would likely continue to exercise caution with the health insurance industry, opposing moves to increase its influence on healthcare pricing while advocating for increased accessibility.

A Harris presidency would likely be pro-science and pro-R&D, including increased funding for HHS and NIH. She would continue to advocate for drug price reductions and expanded healthcare access through Medicare and private insurance. The ongoing investigation into PBMs could lead to a more nuanced approach to drug pricing. Policy developments, as well as macroeconomic factors, can impact biotech investment, from seed funding to IPOs.

← Older Entries
Newer Entries →